[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8E-vnDRyHm943vVLkpounY3qQYFwhUMTZEPUWYE2mag":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":42,"rows":49},"Fundació Sant Joan de Déu",[4],69,false,19,3,25110,2,52,[14,17,19,21,23,25,27,29],{"name":15,"count":16},"Autism Spectrum Disorder",4,{"name":18,"count":16},"Psychosis",{"name":20,"count":9},"Depression",{"name":22,"count":11},"Anxiety",{"name":24,"count":11},"Adherence, Medication",{"name":26,"count":11},"Obesity, Childhood",{"name":28,"count":11},"Obesity, Adolescent",{"name":30,"count":11},"Schizophrenia",[32,37],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT07469215","Behavioral Parent Training With and Without AI Support for Children With Disruptive Behaviors","2027-03","Behavioral Parent Training (BPT) + Support of AI app",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT07033663","Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development","2027-12-01","Monoclonal antibody",[43,44,45,46,47,48],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[50,76,102,139,165,183,209,234,252,278,305,323,352,379,405,423,441,468,486,504,533,551,569,594,619],{"intervention":41,"totalTrials":51,"cells":52},1,{"EARLY_PHASE1":53,"PHASE1":56,"PHASE2":58,"PHASE3":60,"PHASE4":62,"NA":64},{"trials":54,"activeCount":55},[],0,{"trials":57,"activeCount":55},[],{"trials":59,"activeCount":55},[],{"trials":61,"activeCount":55},[],{"trials":63,"activeCount":55},[],{"trials":65,"activeCount":51,"soonestReadout":40},[66],{"nctId":38,"briefTitle":39,"status":67,"phases":68,"primaryCompletion":40,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":75},"RECRUITING",[],"2028-05-01","2018-06-01",90,[73,74],"Pregnancy Related","Immune-mediated Diseases",[41],{"intervention":36,"totalTrials":51,"cells":77},{"EARLY_PHASE1":78,"PHASE1":80,"PHASE2":82,"PHASE3":84,"PHASE4":86,"NA":88},{"trials":79,"activeCount":55},[],{"trials":81,"activeCount":55},[],{"trials":83,"activeCount":55},[],{"trials":85,"activeCount":55},[],{"trials":87,"activeCount":55},[],{"trials":89,"activeCount":51,"soonestReadout":35},[90],{"nctId":33,"briefTitle":34,"status":67,"phases":91,"primaryCompletion":35,"completion":35,"start":92,"enrollment":93,"conditions":94,"interventions":101},[48],"2026-04",40,[95,96,97,98,99,100],"Behavior Problem of Childhood and Adolescence","Parent Management Training","Artificial Intelligence (AI)","Disruptive Behaviours","Irritability","Attention Deficit Disorder With Hyperactivity (ADHD)",[36],{"intervention":103,"totalTrials":11,"cells":104},"Raloxifene",{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":125,"NA":137},{"trials":106,"activeCount":55},[],{"trials":108,"activeCount":55},[],{"trials":110,"activeCount":55},[],{"trials":112,"activeCount":55},[113],{"nctId":114,"briefTitle":115,"status":116,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":123},"NCT01573637","Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women","COMPLETED",[46],"2014-07","2011-07",78,[122],"Schizophrenia in Post Menopausal Women",[103,124],"Lactosa",{"trials":126,"activeCount":55},[127],{"nctId":128,"briefTitle":129,"status":116,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":135},"NCT01041092","Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women",[47],"2009-12","2004-06",34,[30],[136],"raloxifene",{"trials":138,"activeCount":55},[],{"intervention":140,"totalTrials":51,"cells":141},"Reboxetine",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":163},{"trials":143,"activeCount":55},[],{"trials":145,"activeCount":55},[],{"trials":147,"activeCount":55},[],{"trials":149,"activeCount":55},[],{"trials":151,"activeCount":55},[152],{"nctId":153,"briefTitle":154,"status":155,"phases":156,"primaryCompletion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT01300364","Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia","UNKNOWN",[47],"2011-12","2008-11",249,[30],[140,162],"citalopram",{"trials":164,"activeCount":55},[],{"intervention":162,"totalTrials":51,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":181},{"trials":168,"activeCount":55},[],{"trials":170,"activeCount":55},[],{"trials":172,"activeCount":55},[],{"trials":174,"activeCount":55},[],{"trials":176,"activeCount":55},[177],{"nctId":153,"briefTitle":154,"status":155,"phases":178,"primaryCompletion":157,"start":158,"enrollment":159,"conditions":179,"interventions":180},[47],[30],[140,162],{"trials":182,"activeCount":55},[],{"intervention":184,"totalTrials":51,"cells":185},"Low-dose naltrexone",{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":194,"NA":207},{"trials":187,"activeCount":55},[],{"trials":189,"activeCount":55},[],{"trials":191,"activeCount":55},[],{"trials":193,"activeCount":55},[],{"trials":195,"activeCount":55},[196],{"nctId":197,"briefTitle":198,"status":155,"phases":199,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT04739995","Cost-utility and Physiological Effects of LDN in Patients With Fibromyalgia",[47],"2024-10-31","2024-12-31","2022-06-01",99,[205],"Randomized Controlled Trial",[184],{"trials":208,"activeCount":55},[],{"intervention":210,"totalTrials":51,"cells":211},"Glucocorticoids",{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":232},{"trials":213,"activeCount":55},[],{"trials":215,"activeCount":55},[],{"trials":217,"activeCount":55},[],{"trials":219,"activeCount":55},[],{"trials":221,"activeCount":55},[222],{"nctId":223,"briefTitle":224,"status":116,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT02571517","Glucocorticoid Therapy Impact on the Inflammatory Response and Clinical Evolution in Patients With Severe Bronchiolitis",[47],"2013-12","2011-11",94,[230],"Bronchiolitis, Viral",[210],{"trials":233,"activeCount":55},[],{"intervention":124,"totalTrials":51,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":248,"NA":250},{"trials":237,"activeCount":55},[],{"trials":239,"activeCount":55},[],{"trials":241,"activeCount":55},[],{"trials":243,"activeCount":55},[244],{"nctId":114,"briefTitle":115,"status":116,"phases":245,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":246,"interventions":247},[46],[122],[103,124],{"trials":249,"activeCount":55},[],{"trials":251,"activeCount":55},[],{"intervention":253,"totalTrials":51,"cells":254},"TAU",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":274,"NA":276},{"trials":256,"activeCount":55},[],{"trials":258,"activeCount":55},[],{"trials":260,"activeCount":55},[],{"trials":262,"activeCount":55},[263],{"nctId":264,"briefTitle":265,"status":116,"phases":266,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":273},"NCT02561416","Cost-utility and Biological Underpinnings of MBSR in Fibromyalgia Syndrome",[46],"2018-06-30","2018-12-31","2016-01-01",225,[272],"Fibromyalgia Syndrome",[253],{"trials":275,"activeCount":55},[],{"trials":277,"activeCount":55},[],{"intervention":279,"totalTrials":51,"cells":280},"Low molecular weight heparin",{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":287,"PHASE4":301,"NA":303},{"trials":282,"activeCount":55},[],{"trials":284,"activeCount":55},[],{"trials":286,"activeCount":55},[],{"trials":288,"activeCount":55},[289],{"nctId":290,"briefTitle":291,"status":116,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":299},"NCT03324139","Treatment of Intrauterine Growth Restriction With Low Molecular Heparin.",[46],"2022-04-30","2023-02-19","2018-01-25",48,[298],"Intrauterine Growth Restriction",[279,300],"Placebos",{"trials":302,"activeCount":55},[],{"trials":304,"activeCount":55},[],{"intervention":300,"totalTrials":51,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":319,"NA":321},{"trials":308,"activeCount":55},[],{"trials":310,"activeCount":55},[],{"trials":312,"activeCount":55},[],{"trials":314,"activeCount":55},[315],{"nctId":290,"briefTitle":291,"status":116,"phases":316,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":317,"interventions":318},[46],[298],[279,300],{"trials":320,"activeCount":55},[],{"trials":322,"activeCount":55},[],{"intervention":324,"totalTrials":51,"cells":325},"AMPHOTERICIN B",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":346,"PHASE4":348,"NA":350},{"trials":327,"activeCount":55},[],{"trials":329,"activeCount":55},[],{"trials":331,"activeCount":55},[332],{"nctId":333,"briefTitle":334,"status":116,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":345},"NCT01615809","Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia",[45],"2013-07","2011-10",32,[340,341,342,343,344],"Invasive Pulmonary Aspergillosis","Lymphoblastic Leukaemia","Myeloblastic Leukaemia","Lymphoblastic Leukemia","Myeloblastic Leukemia",[324],{"trials":347,"activeCount":55},[],{"trials":349,"activeCount":55},[],{"trials":351,"activeCount":55},[],{"intervention":353,"totalTrials":51,"cells":354},"Dinutuximab. Immunotherapy",{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":373,"PHASE4":375,"NA":377},{"trials":356,"activeCount":55},[],{"trials":358,"activeCount":55},[],{"trials":360,"activeCount":55},[361],{"nctId":362,"briefTitle":363,"status":116,"phases":364,"primaryCompletion":365,"completion":268,"start":366,"enrollment":367,"conditions":368,"interventions":372},"NCT02169609","Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma",[45],"2016-12-26","2014-11-26",24,[369,370,371],"Neuroblastoma","Neoplasm, Residual","Effects of Immunotherapy",[353],{"trials":374,"activeCount":55},[],{"trials":376,"activeCount":55},[],{"trials":378,"activeCount":55},[],{"intervention":380,"totalTrials":51,"cells":381},"Ketamine Hydrochloride",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":399,"PHASE4":401,"NA":403},{"trials":383,"activeCount":55},[],{"trials":385,"activeCount":55},[],{"trials":387,"activeCount":55},[388],{"nctId":389,"briefTitle":390,"status":116,"phases":391,"primaryCompletion":392,"completion":392,"start":393,"enrollment":296,"conditions":394,"interventions":396},"NCT02571491","Comparison of the Efficacy of Ketamine in Pediatric Patients With Idiopathic Scoliosis After Surgery",[45],"2014-02","2012-01",[395],"Progressive Infantile Idiopathic Scoliosis",[380,397,398],"Remifentanil","Morphine hydrochloride",{"trials":400,"activeCount":55},[],{"trials":402,"activeCount":55},[],{"trials":404,"activeCount":55},[],{"intervention":397,"totalTrials":51,"cells":406},{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":417,"PHASE4":419,"NA":421},{"trials":408,"activeCount":55},[],{"trials":410,"activeCount":55},[],{"trials":412,"activeCount":55},[413],{"nctId":389,"briefTitle":390,"status":116,"phases":414,"primaryCompletion":392,"completion":392,"start":393,"enrollment":296,"conditions":415,"interventions":416},[45],[395],[380,397,398],{"trials":418,"activeCount":55},[],{"trials":420,"activeCount":55},[],{"trials":422,"activeCount":55},[],{"intervention":398,"totalTrials":51,"cells":424},{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":435,"PHASE4":437,"NA":439},{"trials":426,"activeCount":55},[],{"trials":428,"activeCount":55},[],{"trials":430,"activeCount":55},[431],{"nctId":389,"briefTitle":390,"status":116,"phases":432,"primaryCompletion":392,"completion":392,"start":393,"enrollment":296,"conditions":433,"interventions":434},[45],[395],[380,397,398],{"trials":436,"activeCount":55},[],{"trials":438,"activeCount":55},[],{"trials":440,"activeCount":55},[],{"intervention":442,"totalTrials":51,"cells":443},"Pioglitazone",{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":462,"PHASE4":464,"NA":466},{"trials":445,"activeCount":55},[],{"trials":447,"activeCount":55},[],{"trials":449,"activeCount":55},[450],{"nctId":451,"briefTitle":452,"status":155,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},"NCT05394142","A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)",[45],"2025-04","2022-05-24",364,[458],"Polycystic Ovary Syndrome (PCOS)",[442,460,461],"Spironolactone","Metformin",{"trials":463,"activeCount":55},[],{"trials":465,"activeCount":55},[],{"trials":467,"activeCount":55},[],{"intervention":460,"totalTrials":51,"cells":469},{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":471,"activeCount":55},[],{"trials":473,"activeCount":55},[],{"trials":475,"activeCount":55},[476],{"nctId":451,"briefTitle":452,"status":155,"phases":477,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":478,"interventions":479},[45],[458],[442,460,461],{"trials":481,"activeCount":55},[],{"trials":483,"activeCount":55},[],{"trials":485,"activeCount":55},[],{"intervention":461,"totalTrials":51,"cells":487},{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":489,"activeCount":55},[],{"trials":491,"activeCount":55},[],{"trials":493,"activeCount":55},[494],{"nctId":451,"briefTitle":452,"status":155,"phases":495,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":496,"interventions":497},[45],[458],[442,460,461],{"trials":499,"activeCount":55},[],{"trials":501,"activeCount":55},[],{"trials":503,"activeCount":55},[],{"intervention":505,"totalTrials":51,"cells":506},"HITS",{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":508,"activeCount":55},[],{"trials":510,"activeCount":55},[],{"trials":512,"activeCount":55},[513],{"nctId":514,"briefTitle":515,"status":116,"phases":516,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":524},"NCT06438614","A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed \u002FRefractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma",[45],"2023-07-20","2023-10-24","2020-08-20",47,[522,523],"Refractory Neuroblastoma","Soft Tissue Cancer",[505,525,526],"Naxitamab + GM-CSF cycles","NICE",{"trials":528,"activeCount":55},[],{"trials":530,"activeCount":55},[],{"trials":532,"activeCount":55},[],{"intervention":525,"totalTrials":51,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":545,"PHASE4":547,"NA":549},{"trials":536,"activeCount":55},[],{"trials":538,"activeCount":55},[],{"trials":540,"activeCount":55},[541],{"nctId":514,"briefTitle":515,"status":116,"phases":542,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":543,"interventions":544},[45],[522,523],[505,525,526],{"trials":546,"activeCount":55},[],{"trials":548,"activeCount":55},[],{"trials":550,"activeCount":55},[],{"intervention":526,"totalTrials":51,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":554,"activeCount":55},[],{"trials":556,"activeCount":55},[],{"trials":558,"activeCount":55},[559],{"nctId":514,"briefTitle":515,"status":116,"phases":560,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":561,"interventions":562},[45],[522,523],[505,525,526],{"trials":564,"activeCount":55},[],{"trials":566,"activeCount":55},[],{"trials":568,"activeCount":55},[],{"intervention":570,"totalTrials":51,"cells":571},"Autologous dendritic cells",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":586,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":573,"activeCount":55},[],{"trials":575,"activeCount":55},[576],{"nctId":577,"briefTitle":578,"status":155,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT02840123","Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines",[44],"2019-03","2016-06",10,[584],"Diffuse Intrinsic Pontine Glioma",[570],{"trials":587,"activeCount":55},[],{"trials":589,"activeCount":55},[],{"trials":591,"activeCount":55},[],{"trials":593,"activeCount":55},[],{"intervention":595,"totalTrials":51,"cells":596},"VCN-01",{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":598,"activeCount":55},[],{"trials":600,"activeCount":55},[],{"trials":602,"activeCount":55},[],{"trials":604,"activeCount":55},[],{"trials":606,"activeCount":55},[],{"trials":608,"activeCount":55},[609],{"nctId":610,"briefTitle":611,"status":116,"phases":612,"primaryCompletion":613,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT03284268","Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma",[48],"2024-06-14","2017-09-06",13,[617],"Retinoblastoma, Recurrent",[595],{"intervention":620,"totalTrials":51,"cells":621},"Antidepressants",{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":630,"NA":632},{"trials":623,"activeCount":55},[],{"trials":625,"activeCount":55},[],{"trials":627,"activeCount":55},[],{"trials":629,"activeCount":55},[],{"trials":631,"activeCount":55},[],{"trials":633,"activeCount":55},[634],{"nctId":635,"briefTitle":636,"status":155,"phases":637,"primaryCompletion":118,"completion":638,"start":639,"enrollment":640,"conditions":641,"interventions":643},"NCT02245373","Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care.",[],"2015-07","2013-06",263,[642],"Mild to Moderate Depression.",[620]]